Original reportsAlvimopan: An oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—A 21-day treatment-randomized clinical trial
Under an Elsevier user license
open archive
Key words
Alvimopan
opioid-induced bowel dysfunction
normalization of bowel function
Cited by (0)
Funded by Adolor Corporation, Exton, Pa.
Copyright © 2005 American Pain Society. Published by Elsevier Inc. All rights reserved.